Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polyethylene glycol + elobixibat is a combination therapy used primarily as a bowel preparation regimen for colonoscopy. Polyethylene glycol (PEG) is an osmotic laxative that retains water in the stool, resulting in softer stools and increased bowel movements. Elobixibat is an ileal bile acid transporter inhibitor that increases the amount of bile acids entering the colon, stimulating colonic secretion and motility. The combination has been shown to provide effective bowel cleansing with good tolerability and less frequent sleep disturbance compared to other regimens such as sodium picosulfate plus PEG[1][2][3]. This regimen is considered an alternative option for patients requiring colonoscopy preparation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyethylene glycol + elobixibat.